SK Biopharmaceuticals has secured an exclusive global license to Biohaven's Kv7 platform drug opakalim, a next-gen treatment for focal epilepsy currently in Phase 2/3 trials with results expected in late 2026. The deal includes $400 million upfront to Biohaven, milestone payments up to $795 million, and tiered royalties on U.S. sales. This partnership leverages SK Biopharmaceuticals' proven epilepsy commercial expertise to bring opakalim to patients worldwide, while Biohaven gains non-dilutive capital and retains long-term revenue potential. The collaboration aims to advance opakalim through FDA approval and global commercialization, offering a novel once-daily oral epilepsy treatment with fewer CNS side effects.
The U.S. Senate failed to pass the CLARITY Act on September 15, falling short of the 60 votes needed. This delays formal crypto legislation but does not end regulatory progress, as the SEC and CFTC plan to act under their existing authority. These ag...
The Walter Family has refuted recent claims that they are reducing their philanthropic efforts, affirming that their financial commitments to various social and environmental causes remain intact. Mark and Kimbra Walter have donated hundreds of milli...
Ethereum price surged past its $2,550–$2,575 resistance zone on September 20, now using this level as support. The token climbed over 75% from $1,510 to $2,650 in three months, marking its second-best quarterly gain on record. Institutional ETF inflo...
Polymarket, a major player in the prediction market sector, is under investigation by the Commodity Futures Trading Commission (CFTC) after a $10 million attempted fraud was uncovered on its U.S. betting platform. The company reportedly rejected 80% ...
In 2024, the AI power trade, which saw surging interest in stocks of power suppliers and equipment makers, has cooled off since June despite rising earnings and positive guidance. This paradox exists because power remains a critical bottleneck for da...
